Pandol and Advil maker Haleon harm by milder flu season
Sales down: Haleon has sold fewer products this year
Panadol and Advil maker Haleon has sold fewer products this year as it feels the sting of a less severe cold and flu season.
Demand for its cough and cold medicines took a hit, and it noted particularly poor performances for its Ibuprofen brand Advil in Canada and cold medicines Contac and Fenbid in China.
The London-listed group said total revenues in the quarter were down 2 per cent on a year earlier, at £2.9billion.
Brian McNamara, chief executive, said although the first quarter was ‘solid’ it was hit by ‘tough comparatives’.
Shares in the company, which was spun out of the drugs giant GSK in 2019, fell 2.5 per cent, or 8.5 p, to 331 p.
The trading update came a day after it said around 436 jobs will be cut by 2026 upon the closure of its Maidenhead site, which makes Sensodyne toothpaste.
Haleon has been on a £300million-a-year cost saving programme.
